CA2453782A1 - Core formulation comprising troglitazone and a biguanide - Google Patents

Core formulation comprising troglitazone and a biguanide Download PDF

Info

Publication number
CA2453782A1
CA2453782A1 CA002453782A CA2453782A CA2453782A1 CA 2453782 A1 CA2453782 A1 CA 2453782A1 CA 002453782 A CA002453782 A CA 002453782A CA 2453782 A CA2453782 A CA 2453782A CA 2453782 A1 CA2453782 A1 CA 2453782A1
Authority
CA
Canada
Prior art keywords
acid
patient
troglitazone
glucopyranosyl
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002453782A
Other languages
English (en)
French (fr)
Inventor
Akwete L. Adjei
Yaping Zhu
Anthony J. Cutie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Kos Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kos Life Sciences Inc filed Critical Kos Life Sciences Inc
Priority claimed from PCT/US2001/021616 external-priority patent/WO2003005993A1/en
Publication of CA2453782A1 publication Critical patent/CA2453782A1/en
Abandoned legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA002453782A 2001-07-10 2001-07-10 Core formulation comprising troglitazone and a biguanide Abandoned CA2453782A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/021616 WO2003005993A1 (en) 2000-05-01 2001-07-10 Core formulation comprising troglitazone and a biguanide

Publications (1)

Publication Number Publication Date
CA2453782A1 true CA2453782A1 (en) 2003-01-23

Family

ID=32067644

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002453782A Abandoned CA2453782A1 (en) 2001-07-10 2001-07-10 Core formulation comprising troglitazone and a biguanide

Country Status (5)

Country Link
EP (1) EP1429740A4 (de)
JP (1) JP2004536842A (de)
AU (1) AU2001273290B2 (de)
CA (1) CA2453782A1 (de)
MX (1) MXPA04000181A (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416774B1 (en) * 1996-05-09 2002-07-09 The Trustees Of The University Of Pennsyvania Hollow bone mineral-like calcium phosphate particles
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
DE69939485D1 (de) * 1998-11-12 2008-10-16 Smithkline Beecham Plc Arzneimittel zur gesteuerten freisetzung eines insulin sensibilisators und metformin
DE19860699A1 (de) * 1998-12-30 2000-07-06 Hexal Ag Pharmazeutische Zusammensetzung
US6358531B1 (en) * 1999-02-01 2002-03-19 The Curators Of The University Of Missouri Method for preparing porous shells or gels from glass particles
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
WO2001035940A2 (en) * 1999-11-16 2001-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
US6451342B2 (en) * 2000-05-01 2002-09-17 Aeropharm Technology Incorporated Core formulation comprised of troglitazone and a biguanide

Also Published As

Publication number Publication date
JP2004536842A (ja) 2004-12-09
MXPA04000181A (es) 2004-11-22
EP1429740A1 (de) 2004-06-23
EP1429740A4 (de) 2005-01-26
AU2001273290B2 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
US6524621B2 (en) Core formulation
US6451342B2 (en) Core formulation comprised of troglitazone and a biguanide
US6403121B1 (en) Core formulation
US6780432B1 (en) Core formulation
US6296874B1 (en) Core formulation comprising troglitazone and abiguanide
KR20010080419A (ko) 인슐린 감작제 및 다른 항당뇨병 약제의 개선된 방출을위한 제약 조성물
US6461639B2 (en) Core formulation
AU2002253768A1 (en) Gastric acid secretion inhibiting composition
US10045973B2 (en) Compositions and methods for treating nocturnal acid breakthrough and other related disorders
AU2001273289B2 (en) Core formulation comprising pioglitazone hydrochloride and a biguanide
KR100732599B1 (ko) 조절 방출형 인슐린 감작제용 제약 조성물
AU2001273289A1 (en) Core formulation comprising pioglitazone hydrochloride and a biguanide
AU2001273310B2 (en) A core formulation
WO2007007757A1 (ja) PPARγアゴニストを含有する医薬組成物
EP1278513B1 (de) Kernformulierung
AU2001273310A1 (en) A core formulation
AU2001257456A1 (en) A core formulation
CA2562009A1 (en) (r,r)-formoterol in combination with other pharmacological agents
AU2001273290B2 (en) Core formulation comprising troglitazone and a biguanide
AU2001273290A1 (en) Core formulation comprising troglitazone and a biguanide

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued